The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

Inclusion Criteria:

• Age over 18 years
• Written informed consent of the patient to participate in the study

Exclusion Criteria:

• Age under 18
• Pregnancy, lactation
• Very high cardiovascular risk
• Life-threatening, independently influencing prognosis and disabling diseases,
• Mental disorders that do not allow to give informed consent or answer questions adequately
• Refuse of the patient to participate in the study

Considering the different severity of psoriasis, it is possible to divide patients with psoriasis into several subgroups: patients with mild psoriasis; patients with moderate psoriasis; patients with severe psoriasis who are not receiving systemic therapy; patients with severe psoriasis receiving systemic therapy with genetic-engineering biological drugs; patients with psoriatic arthritis receiving genetic-engineering biological drugs.